Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections

Int J Antimicrob Agents. 2020 Feb;55(2):105844. doi: 10.1016/j.ijantimicag.2019.11.001. Epub 2019 Nov 9.

Abstract

Endolysins are the lytic products of bacteriophages which play a specific role in the release of phage progeny by degrading the peptidoglycan of the host bacterium. In the light of antibiotic resistance, endolysins are being considered as alternative therapeutic agents because of their exceptional ability to target bacterial cells when applied externally. Endolysins have been studied against a number of drug-resistant pathogens to assess their therapeutic ability. This review focuses on the structure of endolysins in terms of cell binding and catalytic domains, lytic ability, resistance, safety, immunogenicity and future applications. It primarily reviews recent advancements made in evaluation of the therapeutic potential of endolysins, including their origin, host range, applications, and synergy with conventional and non-conventional antimicrobial agents.

Keywords: Antibiotic resistance; Bacteriophages; Holin; Lysin.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacteria / drug effects*
  • Bacterial Infections / drug therapy*
  • Bacteriophages / enzymology*
  • Bacteriophages / metabolism
  • Catalytic Domain
  • Cell Wall / metabolism
  • Communicable Diseases / drug therapy
  • Drug Resistance, Multiple, Bacterial
  • Endopeptidases / pharmacology*
  • Host Specificity
  • Humans
  • Peptidoglycan / metabolism

Substances

  • Anti-Bacterial Agents
  • Peptidoglycan
  • Endopeptidases
  • endolysin